The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.
September 21, 2020
Texas A&M Neuroscientists Discover New Therapy for Refractory Epilepsy
Using an arithmetic technique to select the best combination two medications with the highest efficacy, researchers state that there is a positive interaction between two neurosteroids brexanolone and ganaxolone and two antiepileptic medications tiagabine and midazolam.
September 16, 2020
Body Cooling May Shorten Refractory Seizures in Dravet and Other Epilepsies
Used in addition to standard treatments, therapeutic hypothermia – based on lowering the body’s temperature – can shorten the duration of long-lasting seizures in drug-resistant forms of epilepsy, a study finds.